Aquatic Capital Management LLC Has $1.15 Million Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Aquatic Capital Management LLC increased its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 3,486.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 89,655 shares of the biopharmaceutical company's stock after buying an additional 87,155 shares during the quarter. Aquatic Capital Management LLC owned about 0.07% of Dynavax Technologies worth $1,145,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in DVAX. Russell Investments Group Ltd. increased its stake in shares of Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 1,169 shares during the period. Smartleaf Asset Management LLC increased its holdings in shares of Dynavax Technologies by 463.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 2,034 shares during the period. GAMMA Investing LLC raised its stake in shares of Dynavax Technologies by 55.1% during the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock valued at $52,000 after purchasing an additional 1,457 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in Dynavax Technologies during the 4th quarter valued at about $71,000. Finally, Nisa Investment Advisors LLC lifted its stake in shares of Dynavax Technologies by 19.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock worth $83,000 after acquiring an additional 1,076 shares during the period. 96.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. The Goldman Sachs Group dropped their price objective on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th. StockNews.com raised shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Monday, February 24th. William Blair restated an "outperform" rating on shares of Dynavax Technologies in a report on Friday, February 21st. Finally, HC Wainwright restated a "buy" rating and issued a $31.00 target price on shares of Dynavax Technologies in a report on Friday, February 21st.

Dynavax Technologies Stock Down 1.3 %

Shares of Dynavax Technologies stock traded down $0.15 on Friday, hitting $11.33. 1,750,419 shares of the company traded hands, compared to its average volume of 2,202,122. Dynavax Technologies Co. has a 12-month low of $9.74 and a 12-month high of $14.63. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The company has a market cap of $1.39 billion, a PE ratio of 62.94 and a beta of 1.26. The company has a 50-day moving average price of $12.59 and a 200 day moving average price of $12.58.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting analysts' consensus estimates of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The firm had revenue of $72.03 million for the quarter, compared to the consensus estimate of $72.70 million. Sell-side analysts predict that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.